Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166241 | 0.99 | KDM4E (0.41) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27166254 | 0.99 | KDM4E (0.41) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27298530 | 0.97 | MEN1 (0.40) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27269072 | 0.95 | MEN1 (0.40) | KDM4EMEN1KMT2AS1PR5S1PR1 | |
| SCHEMBL27165232 | 0.92 | MEN1 (0.38) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27166218 | 0.92 | KDM4E (0.38) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27269284 | 0.92 | FOLH1 (0.38) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL30804758 | 0.91 | FOLH1 (0.35) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27166234 | 0.91 | FOLH1 (0.39) | KDM4EMEN1KMT2AFOLH1S1PR5 | |
| SCHEMBL27166230 | 0.90 | MEN1 (0.47) | KDM4EMEN1KMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721092-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | Bayer Aktiengesellschaft (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260087709-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AG (DE) | 2026-03-26 | — | — | US | claimed |
| US-20250378594-A1 | GENERATING SYNTHETIC REPRESENTATIONS | BAYER AG (DE) | 2025-12-11 | — | — | US | claimed |
| EP-4616420-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | Bayer Aktiengesellschaft (DE) | 2025-09-17 | — | — | EP | claimed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | claimed |
| EP-4581641-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | Bayer Aktiengesellschaft (DE) | 2025-07-09 | — | — | EP | claimed |
| EP-4581640-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | Bayer Aktiengesellschaft (DE) | 2025-07-09 | — | — | EP | claimed |
| US-20250191242-A1 | GENERATING SYNTHETIC REPRESENTATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-12 | — | — | US | claimed |
| EP-4485474-A2 | GENERATION OF ARTIFICIAL CONTRAST ENHANCED RADIOLOGICAL RECORDINGS | Bayer AG (DE) | 2025-01-01 | — | — | EP | claimed |
| US-20240404255-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-05 | — | — | US | claimed |
| US-20240346718-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED COMPUTED TOMOGRAPHY IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-10-17 | — | — | US | claimed |
| WO-2024100233-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-16 | — | — | WO | claimed |
| WO-2024052156-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | claimed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | claimed |
| WO-2024046832-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | claimed |
| WO-2024046831-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | claimed |
| EP-4720989-A1 | IDENTIFYING ARTIFACTS IN SYNTHETIC MEDICAL RECORDINGS | Bayer Aktiengesellschaft (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4721092-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | Bayer Aktiengesellschaft (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024046832-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024046831-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260087709-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | TRRAP, TRHR, TSHR | KDM4E 3463/4885MEN1 289/4885KMT2A 298/4885 |
| US-20250191242-A1 | GENERATING SYNTHETIC REPRESENTATIONS | HRAS, KRAS, PML | KDM4E 4672/4885MEN1 148/4885KMT2A 3365/4885 |
| US-20240404255-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | PML, LGALS8, HRAS | KDM4E 3399/4885MEN1 197/4885KMT2A 2108/4885 |
| US-20250378594-A1 | GENERATING SYNTHETIC REPRESENTATIONS | HRAS, KRAS, PML | KDM4E 4672/4885MEN1 148/4885KMT2A 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.